ImmunityBio (IBRX) Other Non-Current Liabilities (2013 - 2026)

ImmunityBio (IBRX) has 13 years of Other Non-Current Liabilities data on file, last reported at $23.3 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $23.3 million, up 158.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.3 million (up 158.38% YoY), and the FY2025 annual result was $424000.0, down 95.06% from the prior year.
• Other Non-Current Liabilities grew to $23.3 million in Q1 2026 per IBRX's latest filing, from $424000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $118.8 million in Q4 2023 and troughed at $288000.0 in Q1 2022.
• A 5-year average of $24.6 million and a median of $9.0 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 98.21% in 2024, then jumped 16234.75% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $21.6 million in 2022, then surged by 448.95% to $118.8 million in 2023, then sank by 92.78% to $8.6 million in 2024, then sank by 95.06% to $424000.0 in 2025, then soared by 5398.58% to $23.3 million in 2026.
• Business Quant data shows IBRX's Other Non-Current Liabilities at $23.3 million in Q1 2026, $424000.0 in Q4 2025, and $115.2 million in Q3 2025.